ALNY vs RVMD
Alnylam Pharmaceuticals, Inc. and Revolution Medicines, Inc., both Healthcare
Alnylam Pharmaceuticals, Inc. is the larger company at $39B against $38B. Over the past year RVMD returned +336% against -49% for ALNY. The RyuScore puts ALNY ahead, 15 against 7 out of 100.
| Figure | ALNY | RVMD |
|---|---|---|
| Last close | $233 | $190 |
| Market cap | $39B | $38B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 118.1 | n/a |
| 1-year return | -49% | +336% |
| 5-year return | +24% | +542% |
| RyuScoresector-relative, 1–10 | 15/100 | 7/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Alnylam Pharmaceuticals, Inc.
Revenue of $2.5B in H1 2026, net income $370M. Its largest reported line is Amvuttra, 67% of the disclosed total.
Revolution Medicines, Inc.
Open these two in the interactive comparison to add more names, change the period or see the correlation.